NCT00510029

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of GAP-134 Administered Intravenously as a 24-Hour Infusion to Healthy Subjects.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 72 (estimated)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 50 Years
• Healthy volunteers: Accepted

Summary

The study will assess the safety, tolerability and pharmacokinetics of single intravenous (IV) doses of GAP-134 in healthy subjects. GAP-134 will be administered as a 24-hour infusion.

Conditions

• Arrhythmia

Interventions

Type	Name	Description
DRUG	GAP-134	atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO

Timeline

• Start date: 2007-09-01
• Primary completion: 2008-01-01
• Completion: 2008-01-01
• First posted: 2007-08-01
• Last updated: 2008-03-13

Locations

1 site across 1 country: United States